

KRAS codon 12 Mutation Status							
Clinical Features	n	Gly12Cys (G12C)	Gly12Val (G12V)	Gly12Asp (G12D)	Gly12Arg (G12R)	Gly12Ala (G12A)	Gly12Ser (G12S)
Stage I	24	10(42)	4(17)	4(17)	3(12)	1(4)	2(8)
Stage II	26	12(46)	5(19)	3(12)	3(12)	2(8)	1(4)
Stage III	42	17(40)	9(21)	5(12)	5(12)	3(7)	3(7)
Stage IV	32	19(60)	5(16)	3(9)	2(6)	2(6)	1(3)
Chemoresistant	51	28(55)	12(23)	4(8)	3(6)	1(2)	3(6)
Chemosensitive	45	11(24)	9(20)	8(18)	7(16)	6(13)	4(9)
Metastatic	47	32(68)	8(17)	3(6)	2(4)	1(2)	1(2)
Non-metastatic	49	12(24)	11(22)	8(16)	9(18)	5(10)	4(8)

**Table S2.** Correlation between KRAS mutation status in lung cancer patients. Numbers in parenthesis indicate percentiles (%) in the total population of patients.